Data / Drug companies / Anthea Pharma Private Limited
Anthea Pharma Private Limited: 23 products in the FDA NDC directory, labeler code 83854
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Anthea Pharma Private Limited (labeler code 83854) lists 23 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 23 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 14, 2026.
The request: Watch Anthea Pharma Private Limited (FDA labeler code 83854): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 83854
- Products in commercial distribution
- 23
- Packages
- 44
- Finished drugs by generic name
- 11
- Prescription products
- 23
- Over the counter products
- 0
- Controlled substance products
- Schedule V 1
- Flagged as original packager
- 13 of 13 products that carry the flag
- Started marketing in the last 12 months
- 15
- Earliest marketing start
- March 21, 2025
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 23 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 23 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Bupivacaine hydrochloride | 5 | 23 |
| Lidocaine hydrochloride | 4 | 134 |
| Ropivacaine hydrochloride | 3 | 20 |
| Ketorolac tromethamine | 3 | 69 |
| Bumetanide | 2 | 42 |
| Fluorescein | 1 | 8 |
| Norepinephrine bitartrate | 1 | 25 |
| Propofol | 1 | 15 |
| Sodium bicarbonate | 1 | 51 |
| Lacosamide | 1 | 57 |
| Olanzapine | 1 | 49 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 19 | 82.6% |
| Injection | 1 | 4.3% |
| Injection, solution, concentrate | 1 | 4.3% |
| Injection, emulsion | 1 | 4.3% |
| Injection, powder, lyophilized, for solution | 1 | 4.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Amide Local Anesthetic | 12 |
| Antiarrhythmic | 4 |
| Cyclooxygenase Inhibitor | 3 |
| Nonsteroidal Anti-inflammatory Drug | 3 |
| Loop Diuretic | 2 |
| Diagnostic Dye | 1 |
| Catecholamine | 1 |
| General Anesthetic | 1 |
| Atypical Antipsychotic | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fluorescein | 83854-048 | Injection | Generic drugs (ANDA) | October 14, 2026 |
| Ketorolac tromethamine | 83854-024 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
| Ketorolac tromethamine | 83854-022 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
| Ketrolac tromethamine | 83854-021 | Injection, solution | Generic drugs (ANDA) | September 25, 2026 |
| Propofol | 83854-018 | Injection, emulsion | Generic drugs (ANDA) | July 14, 2026 |
| Bupivacaine Hydrochloride | 83854-006 | Injection, solution | Generic drugs (ANDA) | April 22, 2026 |
| Bupivacaine Hydrochloride | 83854-005 | Injection, solution | Generic drugs (ANDA) | April 22, 2026 |
| Bupivacaine Hydrochloride | 83854-004 | Injection, solution | Generic drugs (ANDA) | April 22, 2026 |
| Bupivacaine Hydrochloride | 83854-039 | Injection, solution | Generic drugs (ANDA) | April 21, 2026 |
| Bupivacaine Hydrochloride | 83854-038 | Injection, solution | Generic drugs (ANDA) | April 21, 2026 |
| Olanzapine | 83854-003 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 5, 2026 |
| Bumetanide | 83854-035 | Injection, solution | Generic drugs (ANDA) | February 27, 2026 |
| Bumetanide | 83854-007 | Injection, solution | Generic drugs (ANDA) | February 27, 2026 |
| Lacosamide | 83854-002 | Injection, solution | Generic drugs (ANDA) | January 21, 2026 |
| Norepinephrine bitartrate | 83854-017 | Injection, solution, concentrate | Generic drugs (ANDA) | November 25, 2025 |
| Sodium bicarbonate | 83854-001 | Injection, solution | Generic drugs (ANDA) | June 26, 2025 |
| Lidocaine Hydrochloride | 83854-012 | Injection, solution | Generic drugs (ANDA) | April 9, 2025 |
| Lidocaine Hydrochloride | 83854-011 | Injection, solution | Generic drugs (ANDA) | April 9, 2025 |
| Lidocaine Hydrochloride | 83854-010 | Injection, solution | Generic drugs (ANDA) | April 9, 2025 |
| Lidocaine Hydrochloride | 83854-009 | Injection, solution | Generic drugs (ANDA) | April 9, 2025 |
| Ropivacaine hydrochloride | 83854-015 | Injection, solution | Generic drugs (ANDA) | March 21, 2025 |
| Ropivacaine hydrochloride | 83854-014 | Injection, solution | Generic drugs (ANDA) | March 21, 2025 |
| Ropivacaine hydrochloride | 83854-013 | Injection, solution | Generic drugs (ANDA) | March 21, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.